Fremanezumab: Hope for Migraine After Treatment Failures

Research Summary

The PEARL Phase 4 study, published in Cephalalgia, explored the real-world effectiveness of fremanezumab for migraine prevention in patients with at least three previous preventive treatment failures, including onabotulinumtoxinA. Focusing on 398 participants with episodic migraine (40%) and chronic migraine (60%), the study found that 54% of participants achieved a 50% reduction in monthly migraine days over six months following fremanezumab initiation. The responder rate was higher in episodic migraine (67%) compared to chronic migraine (47%). Fremanezumab's safety profile was consistent with earlier findings, and the study supports its effectiveness in challenging real-world settings.

Study Details

📄 Title: Addressing unmet needs in migraine: Real-world fremanezumab effectiveness in participants of the PEARL study with at least three prior preventive treatment failures.

👥 Research Team: Ashina M et al.

📚 Published In: Cephalalgia

📅 Publication Date: 2025 Dec

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.